Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal irinotecan plus cyclophosphamide for relapsed or refractory sarcoma
ChiCTR2500101634Phase 4Not yet recruiting
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Apr 2025
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nanoliposomal irinotecan and cyclophosphamide in osteosarcoma (OS) and soft tissue sarcoma (STS), sponsored by Shanghai Sixth People's Hospital. Primary endpoint: Objective response rate. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecancyclophosphamide
03
Conditions
osteosarcoma (OS)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2500101634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101634.